SARS-CoV-2 Vaccine Efforts

Since the beginning of the COVID-19 pandemic, Immunitrack has initiated several projects to contribute to the ongoing efforts to develop a SARS-CoV-2 vaccine.

Please see below a list of links to pages describing our efforts and a list of resources made available by Immunitrack.

LONG READS

RESEARCH

Spike Mutations – Potential Implications for Vaccine T Cell Responses ▸

Spike mutations: Our epitope binding studies revealed that the D614G variant, first reported in February 2020 and now the most prevalent SARS-CoV-2 strain worldwide, has 100-fold less binding affinity to the most common Caucasian HLA I allele, compared to wild-type Spike. This suggests that the D614G variant may have a lower immunogenic footprint.

RESEARCH

Study of COVID-19 vaccine candidate epitopes reveals low performance of common tools ▸

Our latest research on COVID-19 vaccine candidate epitopes has just been published in Scientific Reports. In the article, we demonstrate that common peptide-MHC prediction tools vary dramatically in performance depending on the predicted allele. The study reveals low performance for common prediction tools when benchmarked on the SARS-CoV-2 peptides assessed in our in vitro complex-stability platform.

RESEARCH

Identification of Novel CD4 and CD8-Stimulating Epitopes From COVID-19 ▸

In response to the COVID-19 pandemic, we applied our NeoScreen technology to identify novel CD8+ and CD4+ T cell epitopes from SAR-CoV-2. We focused on Asian MHC molecules and identified 159 MHC I-binding and 22 MHC II-binding COVID-19-derived epitopes. Collaboration between Immunitrack and Intavis (Germany). Read the free study report and dataset here.

RESEARCH

Spike CD4+ and CD8+ T Cell Epitope Study ▸

Immunitrack performed the most comprehensive HLA restriction study of SARS-CoV-2 Spike-derived epitopes to date. This HLA restriction dataset encompasses 1,200 9-mers overlapping by 8 amino acids that were screened for binding to 9 HLA I and 10 HLA II alleles, respectively. The data is useful in studying patient T cell responses to SARS-CoV-2, and many of the epitopes identified by us have been confirmed independently.

INTERVIEW

NOME: Immunitrack supporting COVID19 vaccine research ▸

Our CEO Stephan Thorgrimsen was interviewed by The Nordic Mentor Network for Entrepreneurship (NOME) about our COVID-19 efforts since the pandemic began. Here, he describes how Immunitrack uses its unique in vitro NeoScreen epitope immunogenicity prediction platform to identify novel SARS-CoV-2 epitopes that are anticipated to elicit strong adaptive immune responses.

INTERVIEW

MVA interview With Immunitrack About the Fight Against the COVID-19 Virus ▸

Immunitrack’s CEO Stephan Thorgrimsen and CSO Sune Justesen speak to David Munis Zepernick from Medicon Valley Alliance about vaccine development in the face of the COVID-19 pandemic. Here, we discuss the importance of CD4+ and CD8+ T cell epitopes in vaccine development and how our epitope prediction technology may contribute to an effective COVID-19 vaccine. Our ongoing collaborations in this area are also mentioned.

RESOURCES

PDF Case Study: Identifying Novel CD4+ and CD8+-Stimulating Epitopes From SARS-CoV-2 ▸

Order: COVID-19 CD8+ Tetramer Panel for Immune Monitoring ▸

Order: Spike CD4+ and CD8+ T cell epitope kits ▸

Watch Immunitrack CEO Stephan Thorgrimsen present COVID-19 efforts at Medicon Valley Allience Annual Meeting ▸

For questions about vaccine development projects

Contact us by email at info@immunitrack.com, by phone using the numbers listed below, or use our online contact form ▸

Tel. +45 2868 2159

Vaccine Links

About us

Immunitrack’s mission is to provide the research community with tools to select or redesign drug candidates at the early stage of R&D but also to provide reagents to monitor lead drug candidates effect on patient’s immune system.

Contact

Immunitrack ApS
Lersø Parkallé 42
2100 Copenhagen Ø
CVR: 32347908

info@immunitrack.com
Tel. +45 28682159

Legal
Follow us